CovalX AG, founded in 2006, specializes in providing advanced technology and services in the field of epitope mapping and protein interaction analysis using mass spectrometry. The company serves major pharmaceutical companies and academic laboratories globally, with support offices in Switzerland, France, and the USA. CovalX's business model revolves around offering cutting-edge products and services that facilitate the detailed study of protein interactions, which are crucial for drug development and other biotechnological applications. The company generates revenue through the sale of its proprietary mass spectrometry equipment and related services, including consulting and technical support. CovalX's innovative solutions, such as polymer-based metal nano-coated disposable targets, address common challenges in mass spectrometry, ensuring high precision and reliability in protein analysis. The company's commitment to ethical standards and continuous innovation positions it as a leader in the biotechnological research market.

Keywords: mass spectrometry, epitope mapping, protein interaction, pharmaceutical, biotechnology, drug development, polymer-based targets, global support, ethical standards, innovation.